Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Updates FY 2026 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 1.200-1.346 for the period, compared to the consensus earnings per share estimate of 1.200. The company issued revenue guidance of $52.1 billion-$54.5 billion, compared to the consensus revenue estimate of $53.2 billion.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BAYRY shares. UBS Group raised shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 9th. Finally, Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Up 0.2%

BAYRY opened at $10.88 on Tuesday. Bayer Aktiengesellschaft has a 1-year low of $6.20 and a 1-year high of $14.85. The company has a current ratio of 1.01, a quick ratio of 0.63 and a debt-to-equity ratio of 1.22. The stock has a market capitalization of $42.76 billion, a price-to-earnings ratio of -9.80 and a beta of 0.62. The business has a 50 day moving average of $11.31 and a 200-day moving average of $10.91.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its earnings results on Wednesday, March 4th. The company reported $0.18 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.18. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. The business had revenue of $13.24 billion for the quarter, compared to analyst estimates of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. As a group, sell-side analysts anticipate that Bayer Aktiengesellschaft will post 1.2 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.